Hence, PD-1 pathway inhibitors should not be completely disregarded as ineffective in prostate cancer treatment, and in a recent trial with pembrolizumab 3/10 patients had an almost complete PSA regression [44]. Here, KLK3 is linked to Familial prostate cancer.